





Helicobacter Pylori

The Soweto Experience





Robert Koch (1843 - 1910)


Koch's Postulates:

① The microorganism must be found in abundance in all organisms suffering from the disease, but should not be found in healthy organisms.


② The microorganism must be isolated from a diseased organism and grown in pure culture.

③ The cultured microorganism should cause disease when introduced into a healthy organism.


④ The microorganism must be reisolated from the inoculated, diseased experimental host and identified as being identical to the original specific causative agent.



The Clinical Outcomes of *Helicobacter pylori* Infections



B



Cancers 2011, 3, 3018-3028; doi:10.3390/cancers3033018

OPEN ACCESS

cancers

ISSN 2072-6694

www.mdpi.com/journal/cancers

Review

Detouring the Undesired Route of *Helicobacter pylori*-Induced Gastric Carcinogenesis

Eun-Hee Kim ¹, Kyung-Sook Hong ¹, Hua Hong ¹ and Ki Baik Hahm ^{1,2,*}

Original research

Mass eradication of *Helicobacter pylori* to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands

Tsung-Hsien Chiang,^{1,2,3} Wei-Jung Chang,⁴ Sam Li-Sheng Chen,⁵

2020

Design Mass eradication of *H. pylori* infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent *H. pylori* infection. Test positives for the ¹³C-urea breath test



National Institutes of Health (NIH) (.gov)

<https://www.ncbi.nlm.nih.gov> › articles › PMC7815911

Mass eradication of *Helicobacter pylori* to reduce gastric ...

by TH Chiang · 2021 · Cited by 201 — Although mass eradication of *Helicobacter pylori* has been proposed as a means to **eliminate gastric cancer**, its long-term effects remain unclear.

control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence and mortality during the chemoprevention period was 53% (95% CI 30% to 69%, $p < 0.001$) and 25% (95% CI -14% to 51%, $p = 0.18$), respectively. No significant changes were noted in the incidence

postulated that it may increase acid reflux to the oesophagus and even lead to an increase in oesophageal adenocarcinoma.¹⁴ Antibiotic treatment also has the potential to disrupt the gut microbiota, which might produce unknown consequences.¹⁵ Finally, there is concern regarding its effect on global antimicrobial resistance or emergence of antibiotic-resistant strains of *H. pylori*.^{16 17} These potentially collateral effects of *H. pylori* eradication are largely theoretical and real-world evidence is urgently needed to throw light on the benefits and harms.


RESEARCH

Open Access




The global prevalence of gastric cancer in *Helicobacter pylori*-infected individuals: a systematic review and meta-analysis

Maryam Shirani^{1†}, Reza Pakzad^{2,3†}, Mohammad Hossein Haddadi⁴, Sousan Akrami^{5,6}, Arezoo Asadi⁷, Hossein Kazemian⁴, Melika Moradi⁶, Vahab Hassan Kaviar⁸, Abolfazl Rafati Zomorodi⁹, Saeed Khoshnood^{3,4}, Mahnaz Shafieian¹⁰, Ronia Tavasolian¹¹, Mohsen Heidary^{12,13*} and Morteza Saki^{6*}



Review

Gastric Cancer Epidemiology: Current Trend and Future Direction


Chidozie Declan Iwu ^{1,*} and Chinwe Juliana Iwu-Jaja ² 

¹ School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa


² Department of Global Health, Stellenbosch University, Stellenbosch 7602, South Africa

* Correspondence: chidoziedelan@gmail.com

Figure 1. Estimated age-standardized global incidence rates of GC in 2020. Source: [9].




Risk of gastric cancer in the second decade of follow-up after *Helicobacter pylori* eradication

Susumu Take^{1,3} · Motowo Mizuno²  · Kuniharu Ishiki³ · Chiaki Kusumoto³ · Takayuki Imada³ · Fumihiko Hamada⁴ · Tomowo Yoshida³ · Kenji Yokota⁵ · Toshiharu Mitsuhashi⁶ · Hiroyuki Okada⁷

Conclusions

The longer the follow-up, the greater the risk of developing diffuse-type gastric cancer becomes in patients with mild-to-moderate gastric atrophy at baseline. Endoscopic surveillance should be continued beyond 10 years after cure of *H. pylori* irrespective of the severity of gastric atrophy.

Management of Helicobacter Pylori Infection










Laboratory Techniques

- **1) PCR**
- **2) Culture , Colonies , AB sensitivity**
- **3) Tissue RNA extraction/ recognition**

The outcome of infection by *H. pylori* reflects an interaction between:



3. R Ahmed, Morton D, Ally R, Bardhan KD, Bukofzer S, Oranyeli D, Riedel L, Segal I (1997). H Pylori (HP) resistance to antibiotics at Baragwanath Hospital. SAMJ 87(6): 747.
4. Ally R, Hale M, Morton D, Hadjinicoulou C, Sonnendecker HEM, Bardhan KD, Segal I. Helicobacter Pylori (Hp) in Soweto, South Africa: Cag A status and histopathology in children. (1998). SAGES 36th Congress Proceedings'
5. Ally R, Ahmed R, Mistry R, Khan U, Segal I. Pentagastrin stimulated Acid secretion in a cohort of patients with Gastroduodenal disease (1998). SAGES 36TH Congress Proceedings.
6. Ally R, Ahmed R, Bhaga H, Isaacs R, Mistry R, Lagaud M, Riedel L, Segal I. H pylori conundrums in Soweto.(1998) SAGES 36th Congress Proceedings.
7. Morton D, Ally R, Ahmed R, Bardhan KD, Segal I. A pilot study of the vacuolating cytotoxin gene (Vac A) of H pylori in Sowetans. (1998) SAGES 36th Congress Proceedings.
8. Ally R, Morton D, Bardhan KD, Bukofzer S, Ahmed R, Bhaga H, Isaacs R, Mistry R, Hassan H, Segal I. Helicobacter pylori (Hp) in Soweto, South Africa: i) prevalence in asymptomatic children, ii) prevalence and Cag A status in adults undergoing endoscopy. (1998) SAGES 36th Congress Proceedings.
9. Ally R, Hassan H, Ahmed R, Segal I. Clinical and biochemical parameters in HIV positive patients with oesophageal candidiasis. (1998) SAGES 36th Congress Proceedings.
10. Patchett SE, Zhang ZW, Ally R, Segal I, Farthing MJG. Low pepsinogen a levels and pepsinogen A:C ratio in a population of children and adults from Soweto, South Africa. (1998) SAGES 36th Congress Proceedings
11. Segal I, Ally R, Becker H, Grundling H, Lagaud. A prospective survey of acute abdominal pain in Africa: OMGE research committee project. (1998) SAGES 36th Congress Proceedings.
12. WanWen Su, Berg D, Mistry S, Ally R, Segal I. PCR-based genotyping of Helicobacter Pylori from gastric juice in Sowetans. (1999) SAMJ 89(8): 886.
13. Mistry R, Berg D, Mukhopadyay A, Ally R, Segal I. Helicobacter Pylori and in vitro metronidazole resistance. (1999) SAMJ 89(8): 880.
14. Berg D, Mistry R, Ally R, Segal I. Sequence motifs at the right end of Cag PAI in South Africa (Soweto) Helicobacter Pylori. (1999) SAMJ 89(8):881.
15. Ally R, Mitchell HM, Segal I. Cag A positive H pylori aplenty in South Africa: the first systematic study of H.pylori infection in asymptomatic children in Soweto. (1999) SAMJ 89(8): 884.
16. Kairu S, Lodenyo H, Ally R, Segal I. Clinical spectrums of AIDS patients with particular reference to the gastrointestinal system. (1999) SAMJ 89(8):885.
17. Lodenyo H, Schoub B, Ally R Kairu S, Segal I. Liver function and seroprevalence of HBV and HBC in AIDS patients at Chris Hani Baragwanath Hospital. (1999) SAMJ 89(8):887.
18. Mokhopadhya A, Jeong JY, Berg D, Mistry R, Segal I, Ally R. H pylori DNA from gastric juice and clinical relationship to diagnosis. (2000) SAMJ 90(6): 641


A . BACTERIAL FACTORS

Medical Progress


HELICOBACTER PYLORI INFECTION

SEBASTIAN SUERBAUM, M.D., AND PIERRE MICHETTI, M.D.

N Engl J Med, Vol. 347, No. 15 · October 10, 2002 · www.nejm.org · 1175



cag pathogenicity island (37,000 bp)



The proteins encoded by these genes assemble to form a complex type IV secretion apparatus capable of delivering CagA from the bacterium into host cells

Translocation of CagA into gastric epithelial cells

Phosphorylation of CagA by host-cell kinases c-Src and Lyn

Binding to and activation of cellular phosphatase SHP-2

Growth factor-like response in host cell, cytoskeletal rearrangements



AMERICAN
SOCIETY FOR
MICROBIOLOGY

Journal of
Bacteriology

POPULATION GENETICS AND EVOLUTION

1 June 2000 Volume 182 Issue 11

<https://doi.org/10.1128/jb.182.11.3210-3218.2000>

Differences in Genotypes of *Helicobacter pylori* from Different Human Populations

Dangeruta Kersulyte¹, Asish K. Mukhopadhyay¹, Billie Velapatiño^{1,2}, WanWen Su¹, ZhiJun Pan¹, Claudia Garcia^{1,3}, Virginia Hernandez¹, Yanet Valdez^{1,2}, Rajesh S. Mistry^{1,4}, Robert H. Gilman², Yuan Yuan^{1,5}, Hua Gao^{1,5}, Teresa Alarcón⁶, Manuel López-Brea⁶, G. Balakrish Nair⁷, Abhijit Chowdhury⁷, Simanti Datta⁷, Mutsunori Shirai⁸, Teruko Nakazawa⁸, Reidwaan Ally⁴, Isidore Segal⁴, Benjamin C. Y. Wong⁹, S. K. Lam⁹, Farzad O. Olfat^{10,11}, Thomas Borén¹⁰, Lars Engstrand¹¹, Olga Torres³, Roberto Schneider³, Julian E. Thomas¹², Steven Czinn¹³, Douglas E. Berg^{1,*}

5 STRAINS

TABLE 1


Distribution of *cag* right-junction motifs among major types of *H. pylori* strains

Geographic region	No. (%) of strains				
	Total	Type I	Type II	Type III	Other
South Europe	36	33 (92%)	1 (3%)	2 (6%)	0
Spain	36	33	1	2	0
Latin America	96	89 (93%)	0	6 (6%)	1 (1%)
Peru	68	62	0	6	0
Guatemala	28	27	0	0	1 ^a
Africa	40	40 (100%)	0	0	0
Gambia	8	8	0	0	0
South Africa	32	32	0	0	0
North America	51	45 (88%)	0	2 (4%)	4 (8%)
Louisiana	16	15	0	0	1 ^a
Missouri	7	7	0	0	0
Ohio	13	11	0	1	1 ^a
Tennessee	5	5	0	0	0
West Virginia	10	7	0	1	2 ^b
East Asia	204	1 (0.5%)	194 (95%)	8 (4%)	1 (0.5%)

Distribution of subtypes of type I strains

Geographic region	No. (%) of strains of subtype:			
	Total	Ia	Ib ^a	Ic ^b
Latin America	89	64 (82%)	25 (28%)	0
Guatemala	27	21	6	0
Peru	62	43	19	0
Europe	43	28 (65%)	15 (35%)	0
Spain	33	23	10	0
Sweden	7	2	5	0
Lithuania	3	3	0	0
Africa	40	32 (80%)	8 (20%)	0
Gambia	8	8	0	0
South Africa	32	24	8	0
United States	45	36 (80%)	3 (7%)	6 (13%)
Tennessee	5	4	1	0
Ohio	11	5	1	5
West Virginia	7	6	1	0
Missouri	7	7	0	0

SEQUENCE MOTIFS AT RIGHT END OF *cagA* PATHOGENICITY ISLAND



encourage further analyses of strains from relatively understudied geographic regions and human ethnic groups. Such “geographic genomics” may uncover new genes that affect human infection,



The *Helicobacter pylori* Genome Project: insights into *H. pylori* population structure from analysis of a worldwide collection of complete genomes

Received: 5 September 2023

Accepted: 13 November 2023


Published online: 11 December 2023



Kaisa Thorell^{1,204}✉, Zilia Y. Muñoz-Ramírez^{2,204}, Difei Wang^{3,4},
Santiago Sandoval-Motta^{5,6,7}, Rajiv Boscolo Agostini⁸, Silvia Ghirotto⁸,
Roberto C. Torres⁹, HpGP Research Network*, Daniel Falush⁹,
M. Constanza Camargo^{4,205} & Charles S. Rabkin^{4,206}

Helicobacter pylori, a dominant member of the gastric microbiota, shares co-

Fig. 1: World map of *HpGP* strain origins and population assignments.



The fineSTRUCTURE global analysis revealed four main *H. pylori* population clusters:

Fig. 2: Distance network analyses of the core genome of the *H. pylori* strains studied.





Fig. 5: Summary of population classifications.



Summary of the clustering results using the respective analyses in relation to previously reported MLST and whole genome-based *H. pylori* populations (Hp) and subpopulations (hsp). Colors are based on classifications from the fineSTRUCTURE (fs) analyses visualized in Supplementary Fig. 1, on the $K = 6$ discriminant analysis of principal components, DAPC (Supplementary Fig. 3), and the network clusters (Fig. 2). The topology of the dendrogram to the left is based on the fineSTRUCTURE hierarchical clustering of Supplementary Fig. 1.

Summary of the *HpGP* strain collection

Country	Total number	Non-atrophic gastritis (%)	Intestinal metaplasia (%)	Gastric cancer (%)
Algeria ^a	10	100		
Argentina	10	100		
Bangladesh	10	100		
Brazil	21	48	38	14
Bulgaria ^a	8	100		
Canada	20	35	65	
Chile	46	54	46	
China	10			100
DR Congo ^a	11	91		9
Colombia	45	78	16	7
Costa Rica	8	100		
Dominican Republic ^a	11	91		9
France	21	48		52
Germany	17	59		41
Ghana ^a	2	100		
The Gambia	5	100		
Greece	21	48		52
Guatemala	3	100		
Honduras	26	35	38	27
Indonesia	11	91		9
India	10	100		

Iran	11	91	9	
Israel	10	70	30	
Italy	29	34	34	31
Japan	29	38	21	41
Jordan ^a	10	100		
Kazakhstan ^a	2	100		
Kyrgyzstan ^a	10	100		
Korea	54	19	19	63
Latvia ^a	34	29	24	47
Lithuania	23	43	35	22
Malaysia	19	47	53	
Mexico	22	45		55
Myanmar ^a	12	83		17
Nepal	13	77		23
Nigeria	4	100		
Peru	33	30	24	45
Poland ^a	20	100		
Portugal	30	57	27	17
Russia	10	60		40
Singapore	21	38	33	29
South Africa	9	100		
Spain	106	72	13	15
Sweden	30	33	33	33
Switzerland	15	60	40	
Taiwan	24	42		58


^aGeographical areas from which no *H. pylori* whole-genome sequences were previously available in GenBank

analysis of only a handful of genes rather than whole genomes^{3,4}. The risk of developing disease from *H. pylori* infection varies greatly by geography⁷ and genomic studies of both humans and *H. pylori* are required to identify the factors that modify this risk.

B . HOST FACTORS

- **Immunology**
- **Pathobiology**
- **Stomach Microbiome**
- **Acid Secretion**

1. Immunology/ Pathobiology




NEJM 2002

Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy

JAMES G. FOX¹, PAUL BECK³, CHARLES A. DANGLER¹, MARK T. WHARY¹, TIMOTHY C. WANG³,
HAI NING SHI² & CATHRYN NAGLER-ANDERSON²

¹*Division of Comparative Medicine, Massachusetts Institute of Technology
Cambridge, Massachusetts, 02139, USA*

²*Mucosal Immunology Laboratory, Pediatric Gastroenterology and* ³*Gastroenterology Unit
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Address correspondence to J.G.F.; email: jgfox@mit.edu*



› J Egypt Soc Parasitol. 2008 Apr;38(1):73-84.

Impact of coinfection with *Schistosoma mansoni* on *Helicobacter pylori* induced disease

Sahar A Abou Holw ¹, Medhat M Anwar, Rasha B Bassiouni, Neveen A Hussen, Hend A Eltaweel

Affiliations + expand

PMID: 19143122

› Acta Parasitol. 2021 Sep;66(3):857-862. doi: 10.1007/s11686-020-00330-y. Epub 2021 Feb 17.

Impact of Coinfection with *Schistosoma mansoni* on the Antibody Response to *Helicobacter pylori*

Ashraf Fawzy Mosa Ahmed ¹, Mona Hassan El-Sayad ¹, Hala Shehata Ali ¹, Hend Aly El-Taweel ²


Affiliations + expand

PMID: 33598776 DOI: 10.1007/s11686-020-00330-y

Cell Reports

Concomitant Infection of *S. mansoni* and *H. pylori* Promotes Promiscuity of Antigen-Experienced Cells and Primes the Liver for a Lower Fibrotic Response

Graphical Abstract



Authors

Sonakshi Bhattacharjee,
Raquel Mejías-Luque,
Eva Loffredo-Verde, Albulena Toska,
Michael Flossdorf, Markus Gerhard,
Clarissa Prazeres da Costa

Correspondence

markus.gerhard@tum.de (M.G.),
clarissa.dacosta@tum.de (C.P.d.C.)

In Brief

Co-infection is ubiquitous in human populations and is yet not the most widely studied experimental topic. Bhattacharjee et al. demonstrate that the immunological interaction of two prominent, anatomically isolated human pathogens, *H. pylori* and *S. mansoni*, eventually results in an unusual, mutually ameliorating effect on the detrimental course of both infections.

Highlights

- Co-infection of *H. pylori* and *S. mansoni* results in altered disease-specific pathology

The IgG subclass response to infection is considered to be a biomarker of the T helper cell response, IFN γ having been shown in humans to promote the production of IgG2 subclass antibodies while significantly suppressing the production of IgG1 subclass antibodies (20, 21). Measurement of the relative levels of anti-*H. pylori* IgG1 and IgG2 subclass antibodies in *H. pylori* positive individuals from a developed country has shown the predominant IgG subclass response to be IgG2, a finding that is consistent with a Th1 predominant response (18, 22).



Scandinavian Journal of Gastroenterology >

Volume 37, 2002 - Issue 5

Submit an article

Journal homepage

Enter keywords, authors, DOI, etc

This Journal



Advanced search

40

Views

32

CrossRef
citations to date

0

Altmetric

Research Article

Major Differences in the IgG Subclass Response to *Helicobacter pylori* in the First and Third Worlds

H. M. Mitchell, R. Ally, A. Wadee, M. Wiseman & I. Segal

Pages 517-522 | Published online: 08 Jul 2009

“ Cite this article <https://doi.org/10.1080/00365520252903044>

References

Citations

Metrics

Reprints & Permissions

Read this article






Fig. 1. The IgG1/IgG2 subclass ratio in subjects from Soweto, Australia and Germany. (1 = Sowetan adults with disease (GU, DU and GC); 2 = Sowetan adults, NUD; 3 = Symptomatic Sowetan children with NUD; 4 = German adults with DU; 5 = German adults, NUD; 6 = Australian adults with DU; 7 = Australian adults with NUD.)

In conclusion, the results of the present study provide the first evidence that the host immune response to *H. pylori* infection in an African population differs from that observed in subjects from developed countries. The reason for this



Available online at www.sciencedirect.com

ScienceDirect

Biomedical Journal

journal homepage: www.elsevier.com/locate/bj



Review Article

Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis



Cheng-Yen Kao^a, Bor-Shyang Sheu^b, Jiunn-Jong Wu^{a,c,d,*}

^a Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan

^b Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

^c Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan

^d Department of Biotechnology and Laboratory Science in Medicine, School of Biomedical Science and Engineering, National Yang-Ming University, Taipei, Taiwan



Prof. Jiunn-Jong Wu




Fig. 1 – Schematic diagram of *Helicobacter pylori* infection and pathogenesis. The urease activity and flagella-mediated motility of *H. pylori* facilitate its survival and movement toward the lower mucus gel above the epithelium, followed by several adhesins, including blood-antigen binding protein A, sialic acid-binding adhesin, and other outer membrane proteins interacting with receptors on the host epithelium cells. After successful colonization, toxins, including cytotoxin-associated gene A, and vacuolating cytotoxin A, are involved in damage of host tissue and intracellular replication.

REVIEW: PATHOGENESIS OF *HELICOBACTER PYLORI* INFECTION

S. Freisberg¹, C. Schulz², J. Bornschein³


¹Department of Internal Medicine and Gastroenterology, Helios-Klinikum Berlin-Buch, Berlin, Germany

²Medical Department II, University Hospital, LMU, Munich, Germany

DZIF Deutsches Zentrum für Infektionsforschung, Partner Site Munich, Munich, Germany

³Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals, Headington, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, Oxford, UK

How host regulation of *Helicobacter pylori*-induced gastritis protects against peptic ulcer disease and gastric cancer

Poshmaal Dhar,^{1,2} Garrett Z. Ng,^{1,2} and  Phillip Sutton^{1,2,3}

¹Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia; ²Centre for Animal Biotechnology, School of Veterinary and Agricultural Science, University of Melbourne, Parkville, Victoria, Australia; and ³Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia

Submitted 12 April 2016; accepted in final form 26 July 2016

inflammatory response to this pathogen is regulated and disease does not ensue; in most cases this is successful. From the literature presented here, it is evident that most known innate

1.4.1 The interleukin (IL)-1 gene

The IL-1 gene family on chromosome 2q includes 3 related genes IL-1A, IL-1B and IL-1RN that encodes the pro-inflammatory cytokines IL-1 α , IL-1 β and IL-1ra (receptor antagonist) respectively (13, 23, 45). IL-1 β is a pro-inflammatory cytokine that inhibits the acid secretion by interfering with the acid secretion of the parietal cells in the stomach. It is estimated that IL-1 β is 100 times more potent than a proton pump inhibitor (eg. Omeprazole)(60). IL-1ra is a naturally occurring anti-inflammatory cytokine that competitively binds to IL-1 receptors.

1.4.2 The TNF α cytokine (Tumor necrosis factor alpha)

The TNFA gene maps to chromosome 6p21.3 and spans about 3kb and contains 4exons. TNF α is a pro-inflammatory cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate an acute phase reaction. TNF α has also been associated with inhibiting acid secretion however to a much lesser extent than IL-1 β .

1.4.3 The interleukin (IL)-10 gene

In humans, the IL-10 gene is located on chromosome 1 and consists of 5 exons. IL-10 is an anti-inflammatory cytokine capable of inhibiting the synthesis of pro-inflammatory cytokines as TNF α or IL-1.

1.4.4 The role of Cytokine Polymorphisms

RAPPORT DE STAGE D'OPTION SCIENTIFIQUE

Titre du Rapport

Study of the cytokine gene polymorphisms in the host and its influence in H.pylori related diseases in a South African population

NON CONFIDENTIEL

Option : Biologie
Champ de l'option : Biologie cellulaire
Directeur de l'option : Monsieur Blanquet Sylvain
Directeur de stage : Professeur Mitchell Hazel
Dates du stage : 14 Avril 2007 au 14 juillet 2007
Adresse de l'organisme :
School of Biotechnology & Biomolecular Sciences
The University of New South Wales
Sydney, NSW 2052
Australia

between these polymorphisms and *H. pylori* related disease. Gastric biopsy samples were collected at the time of endoscopic examination from 81 patients attending the Chris Hani Baragwanath Hospital in Soweto. Of these patients 14 were diagnosed with cancer GC, 3 with duodenal ulcer (DU), 31 with gastric ulcer (GU) and 30 with functional dyspepsia (FD) (control group)

Allele/Country group	Number of studies	Mean value (%)	Std. Deviation	P (2 tailed test for equality of means)
IL-1B-511 T allele frequency				
East Asia	16	49.4	3.1	<0.001
Western	8	32.4	3.0	
South Africa	1	60		
IL-1RN 2 allele frequency				
East Asia	12	5.9	3.0	<0.001
Western	9	26.3	2.7	
South Africa	1	23		
IL-10-1082 A allele frequency				
East Asia	5	94.2	2.3	<0.001
Western	9	51.8	6.0	
South Africa	1	70		
IL-10-592 A allele frequency				
East Asia	5	69.4	2.6	<0.001
Western	7	22.0	2.1	
South Africa	1	35		
TNFA-308 A allele frequency				
East Asia	6	7.2	3.1	<0.001
Western	9	16.3	3.6	
South Africa	1	30		

Table 7: Comparison of the mean values of the allele frequencies of the IL-1, IL-10 and TNF-A cytokine polymorphisms between East-Asian populations, Western populations and the South African population.

2.3.1 Frequency of IL-1 genotypes

The frequency of IL-1 genotypes is shown in Table 4.1 for the GC group, in Table 4.2 for the GU group and in Table 4.3 for the DU disease group.

Locus	Genotype	G.C. n (%)	Controls n (%)	Odds ratio	P
IL-1B-511	C/C	4 (10)	4(14)	1	/
	C/T	20(51)	16(53)	1.2 (0.3-4.2)	0.7
	T/T	15(39)	10(33)	1.3 (0.4-4.5)	1
IL-1RN	1.1	28(71)	20(67)	1	/
	1.2	8(20)	7(23)	0.9 (0.7-1.2)	0.8
	1.3	0(0)	2(7)	0.9 (0.7-1.0)	0.3
	1.4	1(3)	1(3)		
	2.2	1(3)	0(0)	1.04 (1-1.10)	1
	2.4	1(3)	0(0)	1.04 (1-1.10)	1

Table 4.1: Distribution of the IL-1B and IL-1RN genotypes in the gastric cancer disease group

Locus	Genotype	G.U. n (%)	Controls n (%)	Odds ratio	P
IL-1B-511	C/C	12(21)	4(14)	1	/
	C/T	18(31)	16(53)	0.5 (0.2-1.3)	0.2
	T/T	28(48)	10(33)	0.9 (0.4-2.5)	1
IL-1RN	1.1	41(70)	20(67)	1	/
	1.2	14(24)	7(23)	1 (0.8-1.3)	0.8
	1.3	1(2)	2(7)	0.9 (0.8-1.1)	0.3
	1.4	1(2)	1(3)		
	2.2	0(0)	0(0)	/	/
	3.2	1(2)	0(0)	1.02 (1-1.1)	1

Table 4.2: Distribution of the IL-1B and IL-1RN genotypes in the gastric ulcer disease group

		n (%)	n (%)		
IL-1B-511	C/C	9(19)	4(14)	1	/
	C/T	21(45)	16(53)	0.8 (0.3-2.2)	1
	T/T	17(36)	10(33)	0.7 (0.2-1.9)	0.5
IL-1RN	1.1	39(83)	20(67)	1	/
	1.2	3(6.5)	7(23)	0.8 (0.6-1)	0.04
	1.3	1(2)	2(7)	1 (0.8-1.2)	1
	1.4	3(6.5)	1(3)		
	1.5	1(2)	0(0)	/	/
	2.2	0(0)	0(0)	/	/

Table 4.3: Distribution of the IL-1B and IL-1RN genotypes in the duodenum ulcer disease group

polymorphisms in IL-1B, IL-1RN, IL-10 and TNF-A and GU or GC. In contrast we found that those with DU had a significantly lower frequency ($p=0.04$) of the IL-1RN 1/2 genotype than controls, resulting in an OR of 0.8 (CI, 0.6-1). The finding that the frequency of the IL-1RN1/2 genotype was lower in the DU patients is consistent with previous findings in the literature (18) that have shown that IL-1RN allele 2 is an independent protective factor for duodenal ulcer disease. An explanation for the

To date, there are no published studies regarding the association between host cytokine polymorphisms and *H. pylori* related diseases in South Africa. While this study will therefore provide important data for future studies in the African population, given the small number of samples analysed and the absence of other published analysis of the South African population, the conclusions drawn from the current study must be confirmed by larger scale studies.

3. Stomach Microbiome

Review

> [Adv Exp Med Biol. 2016;908:393-408. doi: 10.1007/978-3-319-41388-4_19.](#)

Helicobacter pylori, Cancer, and the Gastric Microbiota

Lydia E Wroblewski¹, Richard M Peek Jr²

Affiliations + expand

PMID: 27573782 DOI: [10.1007/978-3-319-41388-4_19](#)





Fig. 19.1 Schematic representation showing the differences in the composition of the human gastric microbiota based on *H. pylori* status. *H. pylori*-negative individuals possess a highly diverse gastric microbiota and exhibit decreased risk of developing gastric adenocarcinoma when compared to *H. pylori* positive individuals who harbor a less diverse microbiota, possess an increased risk for developing gastric adenocarcinoma and concomitant decreased risk for developing esophageal adenocarcinoma


genes can predict obesity with 90 % accuracy [99]. It is tempting to speculate that in the future, it may be possible to identify groups of bacterial taxa present in the stomach that are predictive of gastric disease outcome at specific stages along the Correa cascade. Indeed, it may also be possible to manipulate an individual's specific microbiota to proffer more favorable outcomes following infection with *H. pylori*.

Hypothesis on the impact of other gastric microbiota on gastric cancer development




Schulz, Ther Adv Gastroenterol; 2019

The *H. pylori* dependent and independent phases



Pimentel de Assumpção; Eur J Clin Microbiol Infect Dis; 2019

GASTRIC MICROBIOTA AND GASTRIC DISEASE PROGRESSION




Nota. PLoS Pathog 2017

PMC full text:

[Clin Microbiol Rev. 2010 Oct; 23\(4\): 713-739.](#)

doi: [10.1128/CMR.00011-10](#)





NIH Public Access

Author Manuscript

S Afr Med J. Author manuscript; available in PMC 2013 November 03.

Published in final edited form as:

S Afr Med J. ; 103(4): 255–259.

Gastric adenocarcinoma in Zambia: a case-control study of HIV, lifestyle risk factors, and biomarkers of pathogenesis

Violet Kayamba¹, Akwi W Asombang^{1,2}, Victor Mudenda³, Mpala Mwanza Lisulo¹, Edford Sinkala¹, Stayner Mwanamakondo¹, Isaac Mweemba³, and Paul Kelly^{1,4}

Conclusions—HIV was not associated with gastric cancer and does not explain the apparent change in age distribution in Zambia. Atrophy was common and was not essential for the development of intestinal metaplasia, suggesting that gastric carcinogenesis in Africa does not always follow the Correa pathway.

ORIGINAL RESEARCH



Serum antibodies to selected *Helicobacter pylori* antigens are associated with active gastritis in patients seen at the University Teaching Hospital in Lusaka, Zambia

Violet Kayamba^{1,2}, Julia Butt³, Matthew Gordon Varga⁴, Aaron Shibemba⁵, Maria Blanca Piazuolo⁶, Keith Tucker Wilson^{6, 7}, Kanekwa Zyambo¹, Simutanyi Mwakamui¹, Chola Mulenga¹, Tim Waterboer³, Meira Epplein⁸, Douglas Corbett Heimbürger⁹, Masharip Atadzhanov², Paul Kelly^{1,2,10}

Conclusions

Among Zambian patients seen at a single center, antibodies to *H. pylori* (CagA, VacA, Omp, HcpC, HP0305 and HpaA) were associated with active gastritis.

RESEARCH ARTICLE

Helicobacter pylori infection and hypochlorhydria in Zambian adults and children: A secondary data analysis

Phoebe Hodges^{1,2}, Paul Kelly^{1,2}, Violet Kayamba¹ *

1 Tropical Gastroenterology & Nutrition group, University of Zambia School of Medicine Department of Internal Medicine, Lusaka, Zambia, 2 Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

4. Acid Secretion


Dictum - “NO ACID
NO ULCER”

K. SWARZ 1910



“No acid, no ulcer”

K Schwarz, 1910.



Ernst Kuipers 1995

**The Interrelation between
Helicobacter pylori, chronic
gastritis and gastric cancer.**





CLINICAL MICROBIOLOGY REVIEWS, July 2006, p. 449–490
0893-8512/06/\$08.00+0 doi:10.1128/CMR.00054-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Vol. 19, No. 3


Pathogenesis of *Helicobacter pylori* Infection

Johannes G. Kusters,* Arnoud H. M. van Vliet, and Ernst J. Kuipers

Department of Gastroenterology and Hepatology, Erasmus MC—University Medical Center, Rotterdam, The Netherlands

Pattern of gastritis	Gastric histology	Duodenal histology	Acid secretion	Clinical condition
 <p>Pan-gastritis</p>	<ul style="list-style-type: none"> • Chronic inflammation • Atrophy • Intestinal metaplasia 	<ul style="list-style-type: none"> • Normal 	<ul style="list-style-type: none"> • Reduced 	<ul style="list-style-type: none"> • Gastric ulcer • Gastric cancer
 <p>Antral-predominant</p>	<ul style="list-style-type: none"> • Chronic inflammation • Polymorph activity 	<ul style="list-style-type: none"> • Gastric metaplasia • Active chronic inflammation 	<ul style="list-style-type: none"> • Increased 	<ul style="list-style-type: none"> • Duodenal ulcer





NEJM 2002


Substitute marker for acid secretion

- **PEPSINOGENS**



Pentti Ilmari SIPPONEN

Accuracy of the GastroPanel test in the detection of atrophic gastritis

 Semi Korpela

2015, European journal of gastroenterology & hepatology

	Lot nr 16GC0702	Lot nr 17HC0702	Lot nr 16PA0702	Lot nr 23PB0703
Sample	Gastrin 17	H.pylori	Pepsinogen I	Pepsinogen II
Unit of measure	pmol/l	EIU	ug	ug/l
Control range	8 to 11	40 - 60	33 - 49	23 - 31

Prof. Alley study, Sowetho, South Africa														South Africa Series 2007 / Pentti Sipponen														Pentti Sipponen													
[Redacted]														[Redacted]														[Redacted]													
														Histology: Panel-type Classification														Histology: Panel-type Classification													
Case No.	Antrum	Chr.infl.	Activity	troph:	IM	Hp	Corpus	Chr.infl.	Activity	Atrophy	IM	Hp	Hp Positivity	Remarks	Antrum/Corpus	Name	Date of birth	Sex	Age	Ilectaly:	PGI	PGII	PGI/II	G17b	G17s	HPAB	HP	Gastric SoftD: 27050													
																	dd/mm/yy		y	uu/uu/uu	µg/l	µg/l		pmol	pmol	EIU	+/-														

Prof. Alley study, Sowetho, South Africa

South Africa Series 2007 / Pentti Sipponen

Case No.	Antrum					Corpus					Hp Positivity	Remarks	Antrum/Corpus	Histology: Panel-type Classification	Name	Date of birth	Age	Ilecectomy	PGI	PGII	PGI/II	G17b	G17s	HPAB	HP	Histology: Panel-type Classification	Gastric SoftD: 27050
	Chr.infl.	Activity	troph	IM	Hp	Chr.infl.	Activity	Atrophy	IM	Hp																	
111	2	1	1	1	0	2	1	1	0	1	1	on PPI?	A1/A1	S	PRO111 S	20/02/45	59	###	###	129,1	38,5	3,4	2,8	97,8	+	S	S
112	1	0	0	0	1	2	0	1	1	1	1		S/A1	S	PRO112 S	20/02/45	59	###	###	69,3	11,1	6,2	0,8	55,7	+	S	S
113	2	0	0	0	1	2	0	0	0	1	1		S/S	S	PRO113 S	20/02/45	59	###	###	133,9	31,9	4,2	13,2	2732,6	+	S	S
114	2	0	0	0	2	2	0	0	0	3	1		S/S	S	PRO114 S	20/02/45	59	###	###	92,9	15,3	6,1	4,7	107,7	+	S	S
115	1	0	0	0	1	2	0	0	0	0	1		S/S	S	PRO115 S	20/02/45	59	###	###	78,1	12,7	6,1	2	269,7	+	S	S
116	3	0	0	0	3	2	0	0	0	3	1		S/S	S	PRO116 S	20/02/45	59	###	###	84,9	24,3	3,5	94,8	18633	+	S	S
117	1	0	0	0	2	2	0	0	0	2	1		S/S	S	PRO117 S	20/02/45	59	###	###	81,8	15,9	5,1	7,4	101,6	+	S	S
118	1	0	0	0	2	2	1	0	0	3	1		S/S	S	PRO118 S	20/02/45	59	###	###	56,8	13,4	4,2	6,8	48,4	+	S	S
119	1	0	0	0	2	1	0	0	0	3	1		S/S	S	PRO119 S	20/02/45	59	###	###	81	9,5	8,5	16,3	29,3	-	S	N
120	1	0	0	0	3	2	0	0	0	3	1		S/S	S	PRO120 S	20/02/45	59	###	###	124,7	18,4	6,8	2	33	+	S	S
121	2	0	0	0	3	2	0	0	0	3	1		S/S	S	PRO121 S	20/02/45	59	###	###	72,5	13,4	5,4	5	177,9	+	S	S
122	2	1	0	0	1	2	1	0	0	0	1		S/S	S	PRO122 S	20/02/45	59	###	###	48,2	29,3	1,6	3,5	146	+	S	C
123	2	0	1	0	1	2	1	1	0	1	1		A1/A1	S	PRO123 S	20/02/45	59	###	###	104,6	14	7,5	3,1	190,1	+	S	S
200	CARCINOMA OF INTESTINAL S					1	3	3	3	0	0		?/A3	C	PRO200	20/02/45	59	###	###	5,9	5,2	1,1	134,7	16,1	-	C	C

-----Original Message-----

From: Pentti Sipponen [mailto:pentti.sipponen@s11.fimnet.fi]

Sent: 28. toukokuuta 2008 10:16

To: Paloheimo, Lea

Cc: AletP@ScientificGroup.com; VicusV@ScientificGroup.com; Rao, Venkat

Subject: Re: Prof Alley study in Soweto. Final results with the newGastroSoftD100 version

Anyhow, I believe the result is very good. Especially high specificity of 94,6% and high negative predictive value of 86,9% indicate that GastroPanel can find the healthy stomachs with high percentage. In this sence the results are excellent. Congratulations.

Please do not hesitate to contact us

Best regards,

C . ENVIRONMENTAL FACTORS

- **Altitude**
- **Diet - SALT**

WJGO

World Journal of
Gastrointestinal Oncology

Submit a Manuscript: <http://www.wjgnet.com/esps/>
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
DOI: 10.4251/wjgo.v8.i4.341

World J Gastrointest Oncol 2016 April 15; 8(4): 341-350
ISSN 1948-5204 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.


TOPIC HIGHLIGHT

2016 *Helicobacter pylori*: Global view

***Helicobacter pylori* associated Asian enigma: Does diet deserve distinction?**

Syed Faisal Zaidi

Figure 1



PRO STUDY

- **371 Consecutive Patients**
- **Questionnaire**
- **Endoscopy**
- **Biopsies : 5 sets (Antrum / Corpus)**
 - 1 – histology**
 - 2 – Snap Frozen – PCR (Bacteriology)**
 - 1 – Snap Frozen - RNA extraction**
 - 1 – Culture (Antibiotic sensitivity)**
- **Bloods : Gastropanel , Ig's**

354	Goodman Boxana	09427793	21-09-06	O	1536FreedomChartersq		75	M	OGJ ?Ca
355	William Ngwenya	09445352	26-09-06	O	1554 Zone1 diepkloof	C	53	M	? Ca Stomach
356	Dudu Ann Tsotsetsi	gp08818282	05-10-06	O	236 Zone3 natalspuit Lcn	C	56	F	>pre Pyl GU
357	Rudha Ndlovu	gt09446594	11-10-06	O	2467 kgolaSt Wolmstadt		54	F	GU=bilir reflux
358	Carel de Jager	gp08816853	06-10-06	O	16Ohara st W-turfontein		60		>Gas Ulcer
359	Eric Matha	gt09447343	10-10-06	O			56	M	> GU D1 Ulcer
360	Phumrlele Ngcobo	gt09460621	03-11-06	O	71B zone2 Meadowlnds		36	F	GU+dU
361	Eunice masale	gt09461313	09-11-06	O	5392 Orlando east	9351643	45	F	Multiple GU
3602	S.Myeni	gt0946555	20-11-06	In-P	355 Siphwe Vlg Dobsnvl	C	60	F	Antral GU
3603	Cecelia Shifango	gt09454152	12-12-06	In-P	11907 Zone 9 pimville	C	69	F	? Ca?
3604	Chicoane Doris	gp08830304	02-01-07	In-P	44A White City Jabavu		73	F	mass in stomach?
3605	Evelyn Mothebyowe	08788914	02-01-07	In-P			48	F	???stomach
3606	JohannesMolepo		04-01-07	O	640 White City Jabuvu		46	M	????
3607	Emily Sonti	gp08641921	08-01-07	O	1212MaggulaStMoletsane		77	F	>Gu?Ca
3608	Johannes Soetland	08832759	17-01-07	O	14HtherIndStX14EldoPrk		61	M	Ca stomach
3609	Cattherine Samara	00454923	30-01-07	O			78		>GU-
3610	Edward Nanzini	gp08720254	19-01-07	O	952 Mkhonza St Dube		78	M	> GU
3611	Catherine Cauara	gt09455225	30-01-07	O	421 Fox st Jeppestown		58	F	GU

DISASTER

- **Quantas Flight – delayed for 7 hours**
- **They did not place the box in – 70**
- **Arrived in Sydney – all denatured**

RECENT


DFG form 54.012 – 04/14

Project Description – Project Proposals


Rainer Haas, München, Germany

Stella I. Smith, Lagos, Nigeria

Anna M. Clarke, Alice, South Africa



Ayodeji (James) Idowu





University of Fort Hare
Together in Excellence

**Prevalence, diagnostic accuracy and molecular characterization of *Helicobacter Pylori* strains
from patients with gastroduodenal pathologies in Chris Hani Baragwanath
Academic Hospital, Soweto, South Africa**

By



AYODEJI AKINDELE IDOWU (201516917)

A thesis submitted in fulfilment of the requirements for the degree of

Doctor of Philosophy




Helicobacter pylori patient isolates from South Africa and Nigeria differ in virulence factor pathogenicity profile and associated gastric disease outcome

Pia Palamides¹ , Tolulope Jolaiya², Ayodeji Idowu³, Eva Loell¹, Charles Onyekwere⁴, Rose Ugiagbe⁵, Ifeanyi Agbo⁵, Olufunmilayo Lesi⁶, Dennis Ndububa⁷, Olusegun Adekanle⁷, Manuel Carranza⁸, Reidwaan Ally⁹, Henry Njom³, Isaac A. Adeleye², Ute Harrison¹, Anna Clarke³, Wolfgang Fischer^{1,11}, Stella Smith¹⁰ & Rainer Haas^{1,11} 

RESEARCH ARTICLE

O

Detection of *Helicobacter pylori* and its virulence genes (*cagA*, *dupA*, and *vacA*) among patients with gastroduodenal diseases in Chris Hani Baragwanath Academic Hospital, South Africa

Ayodeji Idowu^{1*} , Asisipho Mzukwa¹, Ute Harrison², Pia Palamides², Rainer Haas², Melvin Mbao³, Razinah Mamdoo³, Jonathan Bolon³, Tolulope Jolaiya⁴, Stella Smith⁵, Reidwaan Ally³, Anna Clarke¹ & Henry Njom¹

Topic: Evaluation of biofilm production of *Helicobacter pylori* strains isolated from gastric biopsies: An *in vitro* study in Chris Hani Baragwanath Academic Hospital South Africa.

Authors' list: Ayodeji Idowu^{1,2*}, Hafeez Mohamed², Priyamvada Pradeep², Razinah Mamdoo¹, Siyanda Mahlasela¹, Nazeer Chopdat¹, Hitendrakumar Bhaga¹, Reidwaan Ally¹

Authors' affiliations

1. African Institute of Digestive Diseases, Division of Gastroenterology, Chris Hani Baragwanath Academic Hospital (CHBAH), Soweto, Johannesburg 2013, South Africa.
2. Austell Pharmaceuticals (Pty) Ltd., 1 Sherborne Road, Parktown 2193, Johannesburg South Africa.

*Corresponding author




Figure 1. Endoscopy findings and *Hp* culture results

Table 2. Comparison of *Hp* biofilm results between PCR vs TCP and CRA

PCR genes	TCP					CRA				
	N-BF	W-BF	M-BF	S-BF	Total	N-BF	W-BF	M-BF	S-BF	Total
<i>K747_10375/homD</i>										
Positive	3	13	18	39	73	6	13	16	38	73
Negative	8	0	0	0	8	8	0	0	0	8
Total	11	13	18	39	81	14	13	16	38	81

Abbreviations: N-BF (Non-biofilm formers); W-BF (Weak biofilm formers); M-BF (Moderate biofilm formers); S-BF (Strong biofilm formers).




Figure 4. Distribution of *Hp* biofilm production and gastric disease pathology of patients

Conclusion

This study showed good performance and synergy among the three methods used in detecting *Hp* biofilm production. It revealed that most *Hp* strains from South Africa are strong biofilm formers and are associated with gastric diseases. Furthermore, the present study has demonstrated that for effective management of *Hp* in the clinical settings, the factor of biofilm formation by the pathogen, besides the burden of antibiotic drug resistance, must also be considered. Further investigations are encouraged to assess the pattern of resistance of *Hp* biofilm against commonly prescribed antibiotic drugs in South Africa. This knowledge will help in better understanding of the disease pathogen and appropriate treatment strategies will be employed against the infections.





With Prof. Barry Marshall (middle), two other students (right front) and H. pylori lab manager (far left).

SUMMARY - Soweto

- **Bacterium – virulent**
- **Host response – Anti inflammatory**
Reduces Inflammation
Mitigation of pathways – cancer
- **Acid secretion – Pepsinogens - surrogate**
- **Gastrtopanel – ideal test for Africa**

